PRECIRIX® PRECIRIX® PRECIRIX®

PRECIRIX®

Precision radiopharmaceuticals for cancer treatment

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. Precirix’ technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

Investment 
details

Staff

45

Location

Belgium

Welcome to our new international investors that have extensive experience in leveraging platform technologies to develop multi-product opportunities.

Ruth Devenyns

CEO

Header Precirix
Partnership Gimv Partnership Gimv Partnership Gimv

Partnership Gimv

Within this partnership, Precirix can count on the experience of Gimv to run further trials and develop its lead program targeting brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline.

Deal Team

Portret Michaël Vlemmix
Michaël
Vlemmix

Partner

Belgium
portret Sandy Blin
Sandy
Blin

Analyst

Germany